1599 / 1851
EORTC 62931
•
Results
–
No difference in 5-year OS (chemo 66·5%, control 67·8%)
•
Conclusions
“Future studies should focus on patients with larger, grade III,
and extremity sarcomas”
Woll PJ, et al. Lancet Oncol. 2012;13(10):1045-54